. Thorax, 30,[657][658][659][660][661][662] Beta-adrenergic function in airways of healthy and asthmatic subjects. We measured the short-term effects of beta-adrenergic blockade with propranolol (0-2 mg/kg iv), followed by stimulation with salbutamol (200 ,ug inhaled), on specific airway conductance (SGaw), heart rate, and systemic blood pressure (BP) in 11 healthy subjects, and 11 symptom-free asthmatics with normal lung function values.
The existence of a bronchodilator influence mediated by the beta-adrenergic receptors, and opposed to the bronchoconstrictor tone of vagal origin (Widdicombe and Sterling, 1970) , is still controversial in normal man. Beta-adrenergic blockade with propranolol has been reported in the literature as producing (a) no effect (Tattersfield, Leaver, and ; (b) no significant bronchoconstriction (Richardson and Sterling, 1969; Zaid and Beall, 1969) ; or (c) significant bronchoconstriction with marked differences (McNeill and Ingram, 1966; Macdonald, Ingram, and McNeill, 1967; Simonsson et al., 1970; Stone, Sarkar, and Keltz, 1973) . The bronchoconstrictor effect of propranolol in patients with asthma is undisputed, although following the work of McNeill (1964) and others (Langer, 1967; Richardson and Sterling, 1969; Zaid and Beall, 1969; Gayrard, Orehek, and Charpin, 1971 and 1972; Jones, 1972) there have been shown to be pronounced individual variations in reaction, overlapping those of normals (Macdonald et al., 1967) . Furthermore, in most experiments the subject's initial lung function was abnormal. In these instances, the difference between the asthmatic and the normal group in bronchial reaction to betablockade might be attributable to abnormal initial values .
We have therefore reevaluated the bronchomotor and cardiovascular effects of propranolol in healthy subjects and in asthmatics with normal respiratory function. We MEASUREMENTS Specific conductance (SGaw) (ml sec-cmH20' litre-') was measured by panting at a frequency of 2 cycles/sec, and a flow-rate of 1 litre/sec (Butler el al., 1960) with the subjects seated in a constant volume body-plethysmograph throughout the study. Simultaneous recordings of airways resistance and thoracic gas volume were made (Electronics for Medicine, DR 8 amplifier-recorder, White Plains, NY). The resistance of the apparatus (0 4 cmH2O litre'1 sec') was subtracted. SGaw was obtained by dividing the reciprocal of the airway resistance by the thoracic gas volume at which the measurement was made. Blood pressure (BP) was measured by sphygmomanometer, and pulse rate was counted at the radial artery before each SGaw measurement. Each examination started at 2.30 pm. After 5 minutes for temperature equilibration, control measurements were made. Next, propranolol (Avlocardyl, ICI Pharma-France, 1 mg/ml, 0-2 mg/kg) was injected into a forearm vein, in approximately 20 sec. SGaw, BP, and pulse rate were measured 5 and 10 minutes later. Following this, two puffs of salbutamol (Ventolin, Glaxo metered aerosol: 100 ytg per puff) were inhaled. The subjects were trained to inhale the aerosol, and then to hold their breath for 5 seconds, in order to obtain maximal particle retention. The nature of the investigation and the possibility of causing temporary aggravation of their condition had previously been explained to the subjects, all of whom were informed volunteers.
Each SGaw value represents an average of three to four measurements. Statistical analysis of the data was made by the t test for paired variables. Each subject served as his own control. The difference between two means was considered not significant (NS) if the P value was larger than 5%.
In order to exclude the possibility of a placebo response three further normal subjects and five asthmatics were subjected to the same tests following injections of saline and propranolol. RESULTS 
CONTROL GROUP (HEALTHY SUBJECTS)
Effects on airways After saline, the three normal subjects showed no change in SGaw. After propranolol, 10 of the 11 subjects had a decrease in SGaw, with individual variations (Fig. 1 ). In six of these 10 the decrease in SGaw was more pronounced at the fifth than at the tenth minute after injection. Mean decrease of SGaw (Table I) was 944% (16 3 ml sec-' cmH2O-' litre'+416; Effects on airways Figure 1 shows that a bronchoconstriction, with individual variations, appears after propranolol in 10 of the 11 patients with asthma. In six of the 11, the fall in SGaw was more marked at the fifth than at the tenth minute after injection. The average fall in SGaw (Table I) 31-5-+-7% (P<0-02) at the fifth, and 29-8+6% (P<0-05) at the tenth minute (Table II) . Effects on heart rate and blood pressure A decrease in heart rate following propranolol occurred in 10 of the 11 patients with asthma:
18-6% (16-0+9 beats/min, P<0-001), as shown in Figure 2 . Heart rate was further decreased, slightly but not significantly, after salbutamol, averaging -2-0+4 beats/min (Table I) . We were unable to relate the cardiovascular and bronchomotor effects of propranolol. In the five further patients, heart rate was not influenced by saline but was decreased by propranolol (-19-5%; P<0-0l).
COMPARISONS BETWEEN GROUPS Figure 1 shows that the bronchomotor responses to propranolol and to salbutamol vary more widely between individuals in the asthmatic group than among the control subjects. The average bronchoconstrictor effect of propranolol is stronger in the asthmatic than in the control group (P<0-01). Six of the 11 patients responded more than the most responsive normal subject. In contrast, the average bronchodilatation produced by salbutamol in the asthmatics was similar to that in the control subjects.
The initial mean heart rate was significantly (P<0-01) higher in the asthmatic group than in the normal group although the decrease in heart rate after propranolol and salbutamol was similar among the asthmatics and the control subjects. Decrease in systolic and diastolic BP were not significant.
DISCUSSION
The observed bronchoconstrictor effects of propranolol support the opinion that there is, in a majority of healthy subjects, a weak bronchodilator sympathetic tone at rest, analogous to that described in animals (Cabezas, Graf, and Nadel, 1971) . Diverging reports on the airway constrictor effects of the drug-induced betareceptor blockade in normal man appearing in the literature can be explained in part by difference in techniques and innate limitations of the methods. Maximal inspirations needed in some methods, as in FEV, and maximal flow-volume curves, decrease the effects of constrictor agents in normal subjects (Nadel and Tierney, 1961) . Voluntary panting remains the 'manoeuvre of choice' for estimating changes in resistance of intrathoracic airways (Mead, 1973) . Hence we have compared our results only to other studies using airway resistance measurements to assess changes in bronchial calibre. It must be kept in mind that this resistance value is determined mostly by the diameter of the large airways.
A direct constrictor effect of propranolol on bronchial smooth muscle has been described in animals (Advenier, Boissier, and Giudicelli, 1972) . However, in our experiment, as well as in others, the dose of drug used was less than that needed to obtain this effect. The antagonistic effect of Mean pulse rate + SE (min-) 86-0 69-2**** 69-6**** 70-8**** 4-0 3-3 4-5 5-6
Pairedcomparisonsofthedifferencesweremadebythettest: * = p <0005;* = p < 0-02;**-p <0-01; I P < 0-001.
previous treatment with atropine, in both experimental animals and human subjects, demonstrated that the bronchoconstrictor influence unmasked by the beta-blockade was indeed that of the vagus (Herxheimer, 1967; Richardson and Sterling, 1969) . Thus parasympathetic activity rp.ay largely account for the variations in the degree of bronchoconstriction after beta-blockade among the general population.
Although the half-life of the drug is more than two hours in man (Paterson et al., 1970; Tattersfield et al., 1973) , we observed a rapid disappearance of the bronchomotor effect of the betablockade in our subjects, the maximum being close to 5 minutes after the injection. That this effect is only transient remains unexplained, and could be due to a spontaneous reduction in vagal tone. Such changes could have been missed in some other studies (Tattersfield et al., 1973) .
In asthmatic subjects the mean bronchoconstrictor effect of propranolol was greater than in normal subjects, and could not be attributed to abnormal initial baseline values. In contrast to previous reports (Macdonald et al., 1967; Zaid and Beall, 1969; Gayrard et al., 1971) we were unable to correlate significantly, in our group of patients in complete remission, the severity of the disease, established from the history, with the bronchial response to betablockade.
In some experiments (Langer, 1967; Grieco and Pierson, 1971; Zaid and Beall, 1969 ) the use of tests needing forced respiratory movements may have artificially increased the bronchoconstrictor effect of propranolol (Gayrard et al., 1974) .
The increased bronchoconstrictor effects of propranolol do not support the assumption of spontaneous 'partial beta-blockade' (Szentivanyi, 1968) , at least for the majority of the subjects tested. Rather they suggest that, with few exceptions, either beta-adrenergic stimuli are more intensive or the beta-receptors are more sensitive in asthmatics than in normal subjects. Since the beta-adrenergic blockade effect on the heart rate was found to be similar in the two groups, this last hypothesis is not supported. Further, an adrenergic hyperactivity could account for the increased resting heart rate of the asthmatic group as compared to normals (Hahn, 1966) .
The marked individual differences in response to beta-blockade cannot be attributed to abnormal initial values of airway resistance in patients with asthma. These differences suggest that asthmatic patients have a variable level of beta-stimulation. This could be explained either by variations of the stimulation from nerve endings and/or the adrenal medulla (Reinberg, Ghata, and Sidi, 1963) , or by variations in receptor sensitivity to similar amounts of stimulants. The absence of individual correlation between changes in heart rate and bronchomotor effects induced by beta-blockade speaks against the last hypothesis. As in normal subjects, the unmasking of vagal bronchoconstrictor activity by propranolol has also been demonstrated in patients with asthma by the antagonistic effect of atropine (Langer, 1967; Macdonald et al., 1967; Grieco and Pierson, 1971; Gayrard et al., 1972) . Again, individual differences in reaction to propranolol could be explained by differences in vagal activity between individuals (Simonsson, Jacobs, and Nadel, 1967) .
The variability in responses to beta-blockade makes a comparison of average group results of little interest. The overlap observed between the bronchial effects of propanolol in normal subjects and asthmatics indicates that asthmatics differ quantitatively rather than qualitatively from normal subjects. As a practical consequence, it seems unwise to give propranolol for therapeutic purposes to the asthmatics, even those without symptoms.
The beta-adrenergic stimulant drug, salbutamol, produces the same bronchodilator effects after beta-blockade in both healthy and asthmatic subjects, although in the latter group the final mean value of SGaw was lower than the initial value because of the more marked bronchoconstrictor effect of propanolol. Thus, as expected, the agonist and antagonist seem to compete with one another for normal receptor bindings. The possible bronchoconstrictor effect of deep inspiration, while the patients inhaled salbutamol aerosol, would have tended to minimize the rise in SGaw. However, this effect would have decreased at the time of the SGaw measurement, 5 minutes later, and .,would be abolished by salbutamol (Gayrard et al., 1974) . 
